New Therapy Combines Wnt Activation and VEGF Inhibition

SZN-8141 is designed to activate Wnt signaling while inhibiting VEGF, bringing 2 therapeutic mechanisms into a single molecule.

By: Daniel Chao, MD, Diana V. Do, MD

Retinal Physician June 24, 2026

Clinical Report: New Therapy Combines Wnt Activation and VEGF Inhibition

Overview

SZN-8141 is a novel therapy designed to activate Wnt signaling while inhibiting VEGF. Preclinical studies indicate superior efficacy compared to monotherapy.

Background

Diabetic macular edema (DME) is a significant cause of vision impairment among patients with diabetes. Current treatments primarily focus on anti-VEGF therapies, which have limitations in efficacy and patient compliance. The development of therapies that combine multiple mechanisms, such as Wnt activation and VEGF inhibition, may offer enhanced therapeutic benefits.

Data Highlights

Preclinical experiments have shown that SZN-8141 demonstrates superior efficacy compared to either Wnt activation or VEGF inhibition alone.

Key Findings

SZN-8141 combines Wnt activation and VEGF inhibition in a single therapeutic agent.
Preclinical studies indicate that this combination may improve outcomes in diabetic eye disease.
The therapy is expected to enter clinical trials later in 2026.
Current anti-VEGF therapies have limitations in dynamic biomarkers and patient compliance.
Wnt signaling is being explored for its potential to repair and restore vasculature.

Clinical Implications

Ongoing clinical trials will be essential to evaluate the safety and efficacy of SZN-8141 in human subjects.

Conclusion

Further clinical data will be crucial to determine the impact of SZN-8141 on patient outcomes.

PentaVision

Retinal Physician